Targeting Wee1-like protein kinase to treat cancer

Drug News and Perspectives

Volumn 23, Issue 7, 2010, Pages 425-429

  Stathis, Anastasios ^a   Oza, Amit ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE 1; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MK 1775; MYT1 PROTEIN; PACLITAXEL; PD 166285; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; PYRIMIDINE DERIVATIVE; S PHASE KINASE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; TOPOTECAN; UNCLASSIFIED DRUG; WEE1 LIKE PROTEIN KINASE; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; WEE1 PROTEIN, HUMAN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIVISION; COLORECTAL CANCER; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ESOPHAGUS CANCER; FATIGUE; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HYPOKALEMIA; LEUKOPENIA; MELANOMA; MITOSIS INDEX; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BIOPSY; SOLID TUMOR; STOMACH CANCER; UTERINE CERVIX CANCER; VOMITING; ANIMAL; CELL CYCLE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 79952117003     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.7.1490760     Document Type: Review

References (28)

1. Sherr, C.J. Cancer cell cycles. Science 1996, 274(5293): 1672-7.
2. Junttila, M.R., Evan, G.I. p53 - a Jack of all trades but master of none. Nat Rev Cancer 2009, 9(11): 821-9.
3. McGowan, C.H., Russell, P. Cell cycle regulation of human WEE1. EMBO J 1995, 14(10): 2166-75.
4. Sancar, A., Lindsey-Boltz, L.A., Unsal-Kacmaz, K., Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73: 39-85.
5. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88(3): 323-31.
6. Molinari, M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000, 33(5): 261-74.
7. Zhou, B.B., Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004, 4(3): 216-25.
8. Bucher, N., Britten, C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008, 98(3): 523-8.
9. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3(4): 513-9.
10. Tse, A.N., Carvajal, R., Schwartz, G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007, 13(7): 1955-60.
11. Parker, L.L., Piwnica-Worms, H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257(5078): 1955-7.
12. Pines, J. Four-dimensional control of the cell cycle. Nat Cell Biol 1999, 1(3): E73-9.
13. Heald, R., McLoughlin, M., McKeon, F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993, 74(3): 463-74.
14. Jin, P., Gu, Y., Morgan, D.O. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996, 134(4): 963-70.
15. Michael, W.M., Newport, J. Coupling of mitosis to the completion of S phase through Cdc34-mediated degradation of Wee1. Science 1998, 282(5395): 1886-9.
16. Wang, Y., Li, J., Booher, R.N., Kraker, A., Lawrence, T., Leopold, W.R., Sun, Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res 2001, 61(22): 8211-7.
17. Wang, Y., Decker, S.J., Sebolt-Leopold, J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004, 3(3): 305-13.
18. Hirai, H., Iwasawa, Y., Okada, M. et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009, 8(11): 2992-3000.
19. Leach, S.D., Scatena, C.D., Keefer, C.J., Goodman, H.A., Song, S.Y., Yang, L., Pietenpol, J.A. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res 1998, 58(15): 3231-6.
20. Zhou, B.B., Li, H., Yuan, J., Kirschner, M.W. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci U S A 1998, 95(12): 6785-90.
21. Chen, G., Shi, L., Litchfield, D.W., Greenberg, A.H. Rescue from granzyme B-induced apoptosis by Wee1 kinase. J Exp Med 1995, 181(6): 2295-300.
22. Hashimoto, O., Shinkawa, M., Torimura, T. et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006, 6: 292.
23. Mizuarai, S., Yamanaka, K., Itadani, H., Arai, T., Nishibata, T., Hirai, H., Kotani, H. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific antitumor drug Wee1 inhibitor. Mol Cancer 2009, 8: 34.
24. A dose escalation study of MK1775 in combination with 5-FU or 5-FU/CDDP in patients with advanced solid tumor. ClinicalTrials.gov Identifier: NCT01047007.
25. A dose escalation study of MK1775 in combination with either gemcitabine, cisplatin, or carboplatin in adults with advanced solid tumors. ClinicalTrials.gov Identifier: NCT00648648.
26. Schellens, J.H., Leijen, S., Shapiro, G.I., et al. A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol [45th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 3510.
27. A study of MK1775 in combination with topotecan/cisplatin in patients with cervical cancer. ClinicalTrials.gov Identifier: NCT01076400.
28. Study with Wee-1 inhibitor MK-1775 and carboplatin to treat ovarian cancer (M10MKO). ClinicalTrials.gov Identifier: NCT01164995.